Arcadia Investment Management Corp MI Buys 11,472 Shares of Becton, Dickinson and Company (NYSE:BDX)

Arcadia Investment Management Corp MI lifted its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 44.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,488 shares of the medical instruments supplier's stock after buying an additional 11,472 shares during the quarter. Becton, Dickinson and Company comprises approximately 1.4% of Arcadia Investment Management Corp MI's holdings, making the stock its 28th biggest position. Arcadia Investment Management Corp MI's holdings in Becton, Dickinson and Company were worth $8,505,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Nicholson Wealth Management Group LLC increased its position in Becton, Dickinson and Company by 123.5% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 6,380 shares of the medical instruments supplier's stock worth $1,447,000 after buying an additional 3,526 shares during the last quarter. Mattern Capital Management LLC increased its holdings in shares of Becton, Dickinson and Company by 6.0% during the 4th quarter. Mattern Capital Management LLC now owns 32,359 shares of the medical instruments supplier's stock worth $7,341,000 after acquiring an additional 1,843 shares during the last quarter. Concurrent Investment Advisors LLC raised its stake in Becton, Dickinson and Company by 15.4% in the 4th quarter. Concurrent Investment Advisors LLC now owns 10,750 shares of the medical instruments supplier's stock valued at $2,439,000 after acquiring an additional 1,438 shares during the period. Handelsbanken Fonder AB lifted its holdings in Becton, Dickinson and Company by 21.5% during the 4th quarter. Handelsbanken Fonder AB now owns 160,977 shares of the medical instruments supplier's stock valued at $36,521,000 after purchasing an additional 28,499 shares during the last quarter. Finally, Mcdaniel Terry & Co. boosted its position in Becton, Dickinson and Company by 2.7% during the fourth quarter. Mcdaniel Terry & Co. now owns 87,660 shares of the medical instruments supplier's stock worth $19,887,000 after purchasing an additional 2,277 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX traded down $0.39 on Friday, reaching $227.54. 1,920,647 shares of the company's stock were exchanged, compared to its average volume of 2,087,390. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The company has a fifty day moving average of $232.86 and a 200-day moving average of $233.34. The company has a market capitalization of $65.34 billion, a price-to-earnings ratio of 37.80, a PEG ratio of 1.63 and a beta of 0.40. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.83%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company declared that its board has initiated a share buyback plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BDX. Barclays raised their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. StockNews.com upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, February 12th. Finally, Piper Sandler upped their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research report on Tuesday, January 28th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company has a consensus rating of "Buy" and an average price target of $278.29.

Insider Buying and Selling

In other news, EVP Roland Goette sold 4,483 shares of the company's stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the sale, the executive vice president now owns 24,345 shares of the company's stock, valued at approximately $5,380,488.45. This represents a 15.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson acquired 1,500 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The stock was purchased at an average cost of $233.62 per share, for a total transaction of $350,430.00. Following the completion of the purchase, the director now directly owns 8,015 shares of the company's stock, valued at $1,872,464.30. The trade was a 23.02 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 10,544 shares of company stock valued at $2,370,309 over the last quarter. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.